Pause
blankRegister With NARSAContact USSeachable Isolate Inventory Database, On-line Strain Request Form Login RequiredStaph LinksRead details about our programFrequently asked questions Home Pageblank
Login Page For Members
Technical Library
News Related to NARSA Project
Presentations / Publications

PRESENTATIONS AND PUBLICATIONS

Publications/ Posters
  1. Genetic changes associated with glycopeptide resistane in S.aureus: Predominance of aminoacid substitutions in YvqF/VraSR by Maebashi Kazunori et al.
  2. Infection Control by Antibody Discription of Bacterial Quorum Sensing Signaling by Junguk Park et al.
  3. In vitro Activity of Oritavancin against ca-MRSA, VISA & DNSSA by Louis Saravolatz et al.
  4. In vitro Activity of Ceftaroline against ca-MRSA, VISA, VRSA, and Daptomycin-nonsusceptible Staph. aureus by Louis D. Saravolatz et al.
  5. Two-Year Study Evaluating the Potential Loss of Methicillin Resistance in a Methicillin-Resistant Staph. aureus Culture Collection by William Veguilla, et al
  6. Detection of Vancomycin - Intermediate S. aurues With the Updated Trek- Sensititre System and the MicroScan System by Rohan Nadarajah et al.
  7. Comparative genomics and DNA array-based genotyping of pandemic Staph aureus strains encoding Panton-Valentine leukocidin by S. Monecke, B. Berger-Bachi, G. Coombs, et al.
  8. Assignment of Staph. aureus isolates to clonal complexes based on microarray analysis and pattern recognition by Stefan Monecke, Peter Slicker, & Ralf Ehricht
  9. Determination of the mutant selection window for clindamycin, doxycycline, linezolid, moxifloxacin, trimethoprim/sulfamethoxizole against community associated MRSA by George P. Allen and Lalithagauri M. Deshpande
  10. Recovery & Indentification of CA MRSA using BBL CHROMagar MRSA II and BBL CHROMagar MRSA by V. Ritter et al.

The 9th NARSA Annual Investigators Meeting Presentations
  1. Role of S. aureus PPB2 in cell wall synthesis and autolysis by Alexander Tomasz & Aude Antignac, The Rockefeller University, NY
  2. Agents of Change: Enterococcal mobile genetic elements and their relations with Staphylococcus aureus by KEITH E. WEAVER, PH.D., UNIVERSITY OF SOUTH DAKOTA, SANFORD SCHOOL OF MEDICINE
  3. Vaccine Protection Against Staphylococcus aureus Pneumonia by Juliane Bubeck Wardenburg, MD, Univ. of Chicago, Depts of Pediatrics & Microbio
  4. NARSA Activities (Past & Future) by Dan F. Sahm, Ph.D., President, Eurofins Medinet, Inc
  5. The NIAID-Sponsored Pathogen Functional Genomics Resource Center: Reaching Out to Scientific Communities by Scott Peterson, PhD, JCVI (the institute formerly known as TIGR)
  6. Network for Antibacterial Resistance in Staphylococcus aureus by N. Kent Peters, Ph.D. , NIAID, NIH
  7. Genetic basis of susceptibility to S. aureus by Hitesh Deshmukh MD, PhD,
  8. Genotyping The NARSA Collection by Barry N. Kreiswirth, PhD, PHRI
  9. Identification of Ligand Specificity Determinants in AgrC by Eddie Geisinger, MD-PhD student
  10. VRSA Update from CDC by Jean B. Patel, PhD, (D)ABMM, Leader, Antimicrobial Resistance Team
  11. Restriction-Modification and its Potential Impact on vanA Transfer by Jodi A. Lindsay
  12. Coagulase-Negative Staphylococci: Genetic Reservoirs for Antimicrobial Resistance- Key Note by Gordon L. Archer MD, Virginia Commonwealth University, School of Medicine
  13. Sensing and Responding to Mechanism of Innate Host Defense in Staphylococci by Michael Otto, PhD, Rocky Mount. Lab, Lab of Human Bacterl Pathogen, NIAID/NIH

The 10th NARSA Annual Investigators Meeting Presentations
  1. NARSA Updates by Dan Sahm, PhD, President, Eurofins Medinet, Chantilly, VA
  2. The Role of Staphyloxanthin in S. aureus Pathogenesis by George Liu, MD, PhD
  3. Rapid MRSA Diagnostics/the Mol Biol of the Targets/Roles in Surveillance by Richard V. Goering, Ph.D.
  4. The Emergence and Spread of S. aureus Strain ST398 by Frank Lowy, PhD, Prof of Med & Pathology, Columbia U, New York, NY
  5. Genes Identified by in silico Haplotype Mapping as Associated w Susceptibility to Staph aureus Infection have mRNA Expression Profiles that Differ bw Susceptible & Resistance Mouse by Strains by Nicole Johnson
  6. MRSA (Messenger RNA Stabilizing Agents) vs. MRSA by Patrick Olson
  7. The Pros of Decolonizing as a Strategy for Hospital Infections by Jan Kluytmans, MD, PhD
  8. MRSA Updates from CDC by Roberta B. Carey, Ph.D.
  9. Drugs in the Pipeline by Helen W. Boucher, MD, FACP
  10. Candida albicans and Staphylococcus aureus Mixed-Species Biofilms by Brian Peters, University of MD. Baltimore
  11. agr Function in Clinical S. aureus Infections by Bo Shopsin, MD-PhD

The 11th NARSA Annual Investigators Meeting Presentations
  1. RNA Stability, New Drug Target by Dr. Paul M. Dunman
  2. IDSA Clinical Practice Guidelines for the Treatment of MRSA Infections by Catherine Liu
  3. Updates from CDC by Dr. Roberta B. Carey
  4. Active Surveillance and Decolonization for MRSA Control: Can We Do Little or Too Much? by Daniel J. Diekema
  5. Updates from NIH by Dr. Clayton Huntley
  6. What Have We and Will We Learn from Staphylococcal Genomics, the Challenges Ahead by Barry Kreiswirth
  7. Hybrid Clones of S.aureus, Evolution and Epidemiology by Dr.Ashley Robinson
  8. Host Gene Expression Signatures of S.aureus by SunHee Ahn
  9. Turning Virulence of Determinants in S.aureus with Small Molecules by Fei Sun
  10. Active Surveillance and Decolonization for MRSA Control: Can We Do Little or Too Much? by Dr. Lance R. Peterson